Business Context and Reporting Period
This Form 8-K Current Report was filed by Athira Pharma, Inc. (trading symbol: ATHA) on January 27, 2022. The filing discloses corporate governance changes, specifically the appointment of a new director and amendments to executive and director compensation arrangements. Note: The request metadata references "Leonabio, Inc.," but the filing text explicitly identifies the registrant as Athira Pharma, Inc.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and compensation policy updates.
Material Changes and Compensation Updates
Board Appointment
- Grant Pickering was appointed as a Class II director effective January 27, 2022, with a term expiring at the 2022 annual meeting.
- Mr. Pickering was appointed to the Compensation Committee.
- He received an initial stock option grant under the standard non-employee director compensation plan.
Executive Compensation (Dr. Mark Litton, CEO)
- Base Salary Increase: Annual base salary increased from $510,000 to $543,400, effective January 1, 2022.
- Bonus Target Increase: Target annual bonus increased from 40% to 50% of annual base salary.
- Change in Control Agreement: An amended agreement was approved providing for:
- Termination outside Change in Control Period: 12 months' salary, 12 months COBRA, and 25% accelerated vesting of 2019 options.
- Termination during Change in Control Period: 18 months' salary, 150% target bonus, 18 months COBRA, and 100% accelerated vesting of service-based equity awards.
Director Compensation Policy Amendments
- Cash Retainers:
- Non-employee director: $35,000/year.
- Board Chair: $30,000/year.
- Audit Committee Chair: $15,000/year; Member: $7,500/year.
- Compensation Committee Chair: $10,000/year; Member: $5,000/year.
- Nominating & Governance Committee Chair: $8,000/year; Member: $4,000/year.
- Equity Awards:
- Initial Award: Options to purchase 27,742 shares, vesting monthly over 36 months.
- Annual Award: Options to purchase 13,871 shares, vesting one year from grant or prior to the next annual meeting.
- Change in Control: Full acceleration of vesting for outstanding awards.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or discuss general business risks. The primary contingency noted is the potential for "parachute payments" under Section 280G of the Internal Revenue Code regarding the CEO's change in control agreement; the agreement includes a "full payment or lesser amount" provision to maximize after-tax benefits without requiring a tax gross-up.
Investor Verification Checklist
- Verify the exact terms of the Amended and Restated Change in Control and Severance Agreement (Exhibit 10.1) to confirm definitions of "cause" and "good reason."
- Review the Outside Director Compensation Policy (Exhibit 10.2) for full details on equity vesting schedules and exercise prices.
- Confirm the impact of the CEO's salary and bonus increase on the company's future operating expenses.
- Check the press release (Exhibit 99.1) for additional context on Grant Pickering's background and qualifications.